Biotech Values

[rogerm]

ITCI had a big price jump today but its sp could go up considerably more if the FDA accepts a sNDA for BPD. Luma reported sig stat P3 in mid 2019. BPD could be a larger indication then schizo because it has less atypical competition. Luma also looked good against BPD2 where most atypicals fail. Luma did have a failed BPD P3 but Luma scored exceptionally well (20 pts on MADRS) only to see a freaky large placebo effect keeping sig stat away. The FDA liked Luma for Schizo in 2019 so I expect they will also like Luma for BPD in 2020.